Published in J Virol on December 01, 2004
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog (2011) 2.68
The cyclophilins. Genome Biol (2005) 2.58
The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology (2007) 2.54
Retroviral restriction factor TRIM5alpha is a trimer. J Virol (2005) 2.52
The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol (2011) 2.44
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol (2006) 2.31
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A (2005) 2.21
Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog (2008) 2.20
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol (2006) 1.98
Cellular proteins in influenza virus particles. PLoS Pathog (2008) 1.96
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol (2006) 1.77
Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology (2007) 1.77
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol (2006) 1.69
Cyclophilin A interacts with diverse lentiviral capsids. Retrovirology (2006) 1.63
Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog (2009) 1.57
Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol (2007) 1.53
Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol (2009) 1.53
The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol (2012) 1.52
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Evolution of cyclophilin A and TRIMCyp retrotransposition in New World primates. J Virol (2005) 1.37
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol (2012) 1.35
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J Virol (2009) 1.32
Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J Virol (2008) 1.30
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
Cyclophilin A levels dictate infection efficiency of human immunodeficiency virus type 1 capsid escape mutants A92E and G94D. J Virol (2008) 1.27
Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection. J Virol (2009) 1.20
Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant. J Virol (2007) 1.13
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
The overlap of small molecule and protein binding sites within families of protein structures. PLoS Comput Biol (2010) 1.12
Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep (2012) 1.12
HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol (2015) 1.11
Control of viral infectivity by tripartite motif proteins. Hum Gene Ther (2005) 1.10
Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol (2010) 1.07
Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. Nat Chem Biol (2010) 1.02
Nature, nurture and HIV: The effect of producer cell on viral physiology. Virology (2013) 1.02
HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358. Retrovirology (2013) 1.01
Nef enhances HIV-1 infectivity via association with the virus assembly complex. Virology (2008) 1.01
Complementary Assays Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells. J Virol (2015) 1.00
Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology (2014) 0.98
Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95
Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J Virol (2010) 0.94
In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog (2014) 0.94
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. Virology (2008) 0.93
Analysis of virion-incorporated host proteins required for herpes simplex virus type 1 infection through a RNA interference screen. PLoS One (2013) 0.92
Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr. J Virol (2006) 0.92
Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol (2007) 0.91
Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One (2012) 0.89
Cyclophilins as modulators of viral replication. Viruses (2013) 0.88
The V86M mutation in HIV-1 capsid confers resistance to TRIM5α by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import. Retrovirology (2013) 0.87
Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One (2008) 0.87
Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. Drug Target Insights (2007) 0.86
Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity. Eur J Pharmacol (2007) 0.85
Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. J Virol (2015) 0.85
Potent lentiviral restriction by a synthetic feline TRIM5 cyclophilin A fusion. J Virol (2010) 0.85
Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. Nat Commun (2016) 0.84
Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication. Retrovirology (2012) 0.84
SIV replication in human cells. Front Microbiol (2012) 0.84
Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. J Virol (2012) 0.83
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. J Virol (2010) 0.82
Productive replication and evolution of HIV-1 in ferret cells. J Virol (2011) 0.82
Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration. PLoS Pathog (2015) 0.82
Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses (2014) 0.81
The nucleoside triphosphate diphosphohydrolase-1/CD39 is incorporated into human immunodeficiency type 1 particles, where it remains biologically active. J Mol Biol (2007) 0.80
Breaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives. Biology (Basel) (2012) 0.80
Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep (2016) 0.80
Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis? Viruses (2013) 0.79
Functional constraints on HIV-1 capsid: their impacts on the viral immune escape potency. Front Microbiol (2012) 0.79
Enhanced autointegration in hyperstable simian immunodeficiency virus capsid mutants blocked after reverse transcription. J Virol (2013) 0.79
Capsid-Dependent Host Factors in HIV-1 Infection. Trends Microbiol (2017) 0.78
Time-Resolved Imaging of Single HIV-1 Uncoating In Vitro and in Living Cells. PLoS Pathog (2016) 0.78
Cyclophilin A-dependent restriction to capsid N121K mutant human immunodeficiency virus type 1 in a broad range of cell lines. J Virol (2013) 0.78
Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells. Mol Ther (2014) 0.78
Identification of HIV inhibitors guided by free energy perturbation calculations. Curr Pharm Des (2012) 0.77
Molecular Architecture of the Retroviral Capsid. Trends Biochem Sci (2016) 0.77
Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion. Vet Immunol Immunopathol (2011) 0.76
Contribution of glutamine residues in the helix 4-5 loop to capsid-capsid interactions in simian immunodeficiency virus of macaques. J Virol (2014) 0.76
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. PLoS One (2016) 0.75
Gene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent manner. PLoS One (2014) 0.75
Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio (2016) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature (2000) 5.60
Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A (2002) 5.02
A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A (2000) 4.88
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat Struct Biol (2002) 3.54
Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol (1997) 3.50
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A (2003) 2.71
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell (1991) 2.58
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A (2002) 2.19
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res Hum Retroviruses (1995) 2.01
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell (1996) 1.94
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1997) 1.84
Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology (1996) 1.74
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc Natl Acad Sci U S A (1997) 1.68
Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol (1996) 1.59
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol (2004) 1.56
In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A. Virology (1999) 1.37
Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci (1997) 1.36
Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure (1997) 1.34
Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A. J Virol (1998) 1.29
Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. J Virol (1997) 1.25
Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity. Virology (1998) 1.17
Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J Virol (2004) 1.14
Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology (1999) 1.13
Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology (2002) 1.11
Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J Immunol (2001) 1.05
Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology (1998) 1.02
Production of ribosome components in effector CD4+ T cells is accelerated by TCR stimulation and coordinated by ERK-MAPK. Immunity (2003) 0.96
Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.93
Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. J Antibiot (Tokyo) (1999) 0.90
Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) (1999) 0.90
Chimeric human immunodeficiency virus type 1 (HIV-1) virions containing HIV-2 or simian immunodeficiency virus Nef are resistant to cyclosporine treatment. J Virol (2004) 0.90
Cryoelectron microscopic examination of human immunodeficiency virus type 1 virions with mutations in the cyclophilin A binding loop. J Virol (1998) 0.90
Conformational state of a 25-mer peptide from the cyclophilin-binding loop of the HIV type 1 capsid protein. Biochem J (1997) 0.82
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature (2011) 6.29
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology (2005) 3.39
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog (2009) 2.92
Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol (2008) 2.41
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A (2005) 2.21
Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol (2002) 2.11
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol (2006) 1.77
Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest (2009) 1.73
AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene (2004) 1.68
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol (2004) 1.56
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity (2004) 1.50
Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol (2002) 1.50
Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med (2007) 1.50
Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol (2005) 1.49
Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol (2006) 1.48
TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol (2012) 1.47
A dual task for the Xbp1-responsive OS-9 variants in the mammalian endoplasmic reticulum: inhibiting secretion of misfolded protein conformers and enhancing their disposal. J Biol Chem (2008) 1.38
TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology (2013) 1.38
Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology (2011) 1.32
Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon. Retrovirology (2011) 1.32
HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. Retrovirology (2012) 1.27
TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol (2011) 1.16
Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J Virol (2004) 1.14
TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol (2012) 1.12
Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol (2005) 1.11
p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol (2010) 1.08
ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol (2005) 1.08
Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol (2005) 1.07
Deciphering the code for retroviral integration target site selection. PLoS Comput Biol (2010) 1.06
Cyclophilin A peptidyl-prolyl isomerase activity promotes ZPR1 nuclear export. Mol Cell Biol (2002) 1.05
Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J Biol Chem (2003) 1.05
Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology (2013) 1.03
Efficient IgM assembly and secretion require the plasma cell induced endoplasmic reticulum protein pERp1. Proc Natl Acad Sci U S A (2009) 1.02
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol (2010) 1.02
Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol (2006) 1.01
The role of lysine 186 in HIV-1 integrase multimerization. Virology (2007) 1.00
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding. J Virol (2009) 0.98
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog (2011) 0.98
TRIM5α associates with proteasomal subunits in cells while in complex with HIV-1 virions. Retrovirology (2011) 0.97
HIV-1 Vpr induces defects in mitosis, cytokinesis, nuclear structure, and centrosomes. Mol Biol Cell (2004) 0.96
Production of ribosome components in effector CD4+ T cells is accelerated by TCR stimulation and coordinated by ERK-MAPK. Immunity (2003) 0.96
Overcoming current limitations in humanized mouse research. J Infect Dis (2013) 0.95
The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA- and DNA-induced activation of interferon beta. J Biol Chem (2009) 0.93
The fate of HIV-1 capsid: a biochemical assay for HIV-1 uncoating. Methods Mol Biol (2014) 0.93
Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells (2008) 0.93
Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One (2010) 0.92
Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol (2007) 0.91
CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction. Am J Respir Crit Care Med (2013) 0.89
Processing strategies and software solutions for data-independent acquisition in mass spectrometry. Proteomics (2015) 0.89
The retroviral restriction factor TRIM5alpha. Curr Infect Dis Rep (2007) 0.87
G2 cell cycle arrest and cyclophilin A in lentiviral gene transfer. Mol Ther (2006) 0.84
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. J Virol (2010) 0.82
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. PLoS One (2012) 0.82
Cyclophilin B interacts with sodium-potassium ATPase and is required for pump activity in proximal tubule cells of the kidney. PLoS One (2010) 0.80
TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. J Virol (2014) 0.78
Mast cells in a murine lung ischemia-reperfusion model of primary graft dysfunction. Respir Res (2014) 0.76
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. medRxiv (2022) 0.75